Skip to main content

Non-Small Cell Lung Cancer Clinical Trials

Review the non-small cell lung cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 276-300 of 460

Difluoromethylornithine in Combination with Pembrolizumab For the Treatment of STK11-Mutant Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Status: Active
Location: 2 locations
A Vaccine for the Treatment of Patients with Advanced ALK Rearrangement Positive Non-Small Cell Lung Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Status: Active
Location: 6 locations
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Status: Active
Location: 2 locations
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
Retifanlimab and Ruxolitinib for the Treatment of Advanced or Metastatic Renal Cell Cancer or Non-small Cell Lung Cancer Progressing on Prior Checkpoint Inhibition, PRISM Trial
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF alone or in Combination with Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Study of NEO-201 in Solid Tumors Expansion Cohorts
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Status: Active
Location: University of California San Francisco, San Francisco, California
RAPA-201 Therapy of Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Gilteritinib for the Treatment of ALK NSCLC
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Vancomycin and Precision Radiation Therapy for the Treatment of Patients with Oligoprogressive Non-small Cell Lung Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania